Severe intestinal vasculitis in a patient under treatment with bortezomib.
Mangiacavalli
Silvia
S
Zappasodi
Patrizia
P
Castagnola
Carlo
C
Astori
Cesare
C
Varettoni
Marzia
M
Lazzarino
Mario
M
Corso
Alessandro
A
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D000069286:Bortezomib; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007410:Intestinal Diseases / Q000139:chemically induced* / Q000150:complications / Q000188:drug therapy; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000601:surgery; D011183:Postoperative Complications / Q000139:chemically induced*; D011719:Pyrazines / Q000009:adverse effects* / Q000627:therapeutic use; D016879:Salvage Therapy / Q000009:adverse effects; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000139:chemically induced* / Q000150:complications / Q000188:drug therapy / Q000209:etiology*
D000893:Anti-Inflammatory Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone